IMAAVY – BiotechReality – Information Intelligence System for Biopharma

Johnson & Johnson has received European Commission (EC) marketing authorization for Imaavy (nipocalimab), marking a significant advancement in the treatment of generalized myasthenia gravis (gMG). The approval establishes the drug as the first neonatal Fc receptor (FcRn) blocker authorized in Europe for a broad patient population that includes both adults and adolescents aged 12 and older. The authorization permits the use of nipocalimab as an add-on to standard therapy for patients who test positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibodies. These two groups represent approximately 90% of the antibody-positive gMG population, a chronic autoimmune disease characterized by fluctuating and often debilitating muscle weakness. Read More: Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) Receives U.S. FDA Approval, a Novel FcRn Blocker for Generalized Myasthenia Gravis Patients Clinical Trials Demonstrate Sustained Control The EC’s decision was underpinned by data from two key studies: the pivotal Phase 3 Vivacity-MG3 study in adults and the Phase 2/3 Vibrance-MG study in adolescents. In the Vivacity-MG3 trial, adult patients receiving nipocalimab alongside standard of care achieved superior disease control compared to those on a placebo over a 24-week period. Notably, data from the study’s open-label extension phase suggested that the drug could offer sustained disease control and symptom relief for up to 20 months. Adolescent data from the Vibrance-MG study echoed these positive results, showing sustained disease control through immunoglobulin G (IgG) reduction over 24 weeks. Nipocalimab is designed to block the FcRn receptor, thereby lowering levels of circulating IgG antibodies a root cause of the disease, without broadly suppressing the immune system. Read More: U.S. FDA Approves Johnson & Johnson’s SIMPONI® (golimumab) for Pediatric Ulcerative Colitis The approval of nipocalimab as the first FcRn blocker to treat a broad population of adults and adolescents living with gMG marks a meaningful advance in addressing persisting unmet needs. Mark Graham Addressing Unmet Needs Myasthenia gravis affects an estimated 56,000 to 123,000 people across Europe. While current treatments exist, many patients continue to experience unpredictable symptom fluctuations that impact daily activities such as speaking, swallowing, and walking. Global Regulatory Momentum This European approval follows similar authorizations for nipocalimab in the United States, Japan, and Brazil. Johnson & Johnson is continuing to explore the drug’s potential across other autoantibody-mediated diseases, including rare maternal-fetal and rheumatic conditions. Nipocalimab is now poised to enter the European market, offering a new mechanism of action for thousands of patients struggling to manage the chronic burdens of gMG. Information: Johnson & Johnson Last Modified:

Tag: IMAAVY

Johnson & Johnson’s Imaavy Wins European Commission Approval for Generalized Myasthenia Gravis

Johnson & Johnson’s IMAAVY™ (nipocalimab-aahu) Receives U.S. FDA Approval, a Novel FcRn Blocker for Generalized Myasthenia Gravis Patients

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment